



ASX ANNOUNCEMENT

1 November 2018

CardieX Strategic Partner Blumio Initiates Large-Scale Clinical Trial to Further Demonstrate Wearable Blood Pressure Sensor Accuracy

Highlights:

- Silicon Valley based Blumio, Inc to initiate 200-person clinical study at US based Deborah Heart and Lung Center.
- Clinical trial expands on previously announced 60-person study significantly enhancing sample size and accuracy of sensor data results.
- Non-randomised study to detect accuracy of Blumio blood pressure sensor compared to arterial line, the current standard in blood pressure monitoring in hospitals.
- Study represents major milestone in further development of Blumio's continuous, non-invasive blood pressure sensor.
- Blumio wearable sensor technology together with CardieX analytics has the potential to disrupt a multi-billion USD market.

CardieX Limited (ASX:CDX, the "Company"), announced today that its strategic partner Blumio, Inc ("**Blumio**") is initiating a clinical study at the US based Deborah Heart and Lung Center. The study aims to further refine the accuracy of Blumio's non-invasive wearable blood pressure sensor which is proposed to be integrated with CardieX's world leading blood pressure analytics technology.

The single-centre, non-randomised study with 200 participants will compare the signal from the Blumio sensor with signals from the current standard in blood pressure monitoring in hospitals, the invasive arterial line, as well as to automated blood pressure cuffs. It is anticipated that the data collected from the study will further validate Blumio's breakthrough technology. The study is anticipated to commence early November, 2018 and will be completed Q1, 2019.

CardieX and Blumio previously entered into a Collaboration and Development Agreement to co-develop wearable blood pressure technology based on Blumio's sensor and CardieX's (AtCor Medical Division) blood pressure analytics algorithms.

Blumio CEO, Catherine Liao stated, "The study will allow us to demonstrate our sensor's accuracy as compared to an arterial line, which is the gold standard in blood pressure monitoring in hospitals. This is a critical step towards the commercialization of our sensor technology."

CardieX CEO, Craig Cooper commented, "This is a very exciting period for CardieX as the study represents a major milestone in the development of Blumio's continuous, non-invasive blood



pressure sensor. As stated above by Ms Liao, this is a critical step toward the commercialization of Blumio's sensor technology which we believe will significantly disrupt the diagnosis and treatment of hypertension and related cardiovascular disorders – a multi-billion USD market."

For more information please contact:

Chief Executive Officer
Craig Cooper
Ph: +61 429 993 399
ccooper@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

About CardieX

CardieX is a Sydney based global health technology company focused on developing technology solutions for large-scale population health disorders.

About Blumio

Blumio is a Silicon Valley based company that develops non-invasive radio frequency sensors designed to measure blood pressure and other cardiovascular diagnostics.